Human Studies Begin for Medication Already Proven 97% Effective in In Vitro (cell) and In Vivo (Animal) Testing
Skymount Medical and Louisiana State University have founded a strong AI platform that has enabled the creation of a COVID-19 oral medication, proven 97% effective in in vitro (cell) and in vivo (animal) testing, in a record thirteen months. By taking this oral medication at the first sign of infection, adults can avoid hospitalization and ICU visits, saving global healthcare systems and helping to end the pandemic. Compassionate use human studies for the oral medication began Tuesday, August 10th in Europe and are expected to continue throughout the United States, the United Kingdom, India, and Brazil.
Deep Drug is the Artificial Intelligence program behind the breakthrough treatment and promises to significantly reduce time to market and capital costs associated with drug recovery. Dr. Supratik Mukhopadhyay, associate professor in the LSU Department of Computer Science and contributing NASA researcher in the field of AI co-founded Deep Drug in conjunction with other LSU researchers. Dr. Mukhopadhyay says, “We are extremely pleased that within 13 months of starting the drug discovery process, we can move to human studies. We could not have accomplished this without AI.”
Skymount Medical is the commercialization agent behind LSU’s ground-breaking AI innovation. Skymount Medical’s CEO, Zubin Kothawala has overseen the delivery of over one billion in IT projects in Afghanistan, Iraq, Africa, and Myanmar including USAID, FEMA, SOCOM, British SF and Nato SF DND Canada. Chris Galliano, the CTO of Skymount Medical, has twenty years of experience in architecting complex enterprise systems including NATO ITM enterprise cloud and the United States Navy’s first Enterprise Data Center within the Navy Marine Corps Intranet (NMCI). He is a Veteran of the United States Navy and has served through Operation Enduring Freedom, Operation Iraqi Freedom, and Operation Unified Assistance where he was awarded the Humanitarian Medal for his works in Indonesia and Sri Lanka.
The collective mission of Skymount Medical and LSU is to accelerate the development of better medicines using Deep Drug and to become the leading provider of innovative treatments to improve global health. For more information about Skymount Medical and the ground-breaking AI platform, Deep Drug, visit www.skymountmed.com.
